Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 659 shares at $43.02 ($28K) on 2025-09-11, disclosed to the SEC on 2025-09-12.
Seasonal sale ($28k) by Chief Development Officer — this insider has traded AKRO in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |
| AKRO | SELL | 2025-05-19 | $786K | — | Filing → |